More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Lampros Milanos, PhD

Research Fellow

Lab Phone

+1 (646) 888-2216


Start Year



PhD, Pharmaceutical Chemistry, University of Erlangen-Nuremberg (GRK1910/DFG) - 10/2016

MSc, Medicinal Chemistry, The University of Glasgow - 09/2013

BSc, Chemistry, University of Ioannina - 07/2011

Areas of Expertise

Organic Synthesis/Medicinal Chemistry

Computational Chemistry


Lampros Milanos received his PhD at the University of Erlangen-Nuremberg funded by a GRK1910/DFG scholarship under the supervision of Dr. Nuska Tschammer and Prof. Timothy Clark. During his PhD, Lampros focused on synthesizing allosteric modulators for the human chemokine receptor CXCR3; a G protein coupled receptor known to be involved in multiple autoimmune diseases, diabetes type 2 and cancer. Efforts led to the discovery of the first biased agonists of the human CXCR3 receptor. The second project of Lampros was the identification of new allosteric sites of CXCR3 using his biased agonists in molecular dynamics simulations, which resulted the identification of an unknown allosteric site. Both discoveries, the high potent biased agonists and their binding modes could significantly enhance the development of new anti-inflammatory drugs.

Lampros is currently a research fellow at Memorial Sloan Kettering Cancer Center in the Chiosis lab and his project combines the design, synthesis and biological characterization of high potency human Grp94 inhibitors. GRP94 (Glucose-regulated protein 94) is a chaperone protein with important roles in tumor development and metastasis. Previously, the Chiosis lab has identified a series of highly selective Grp94 ligands. Lampros’ goal is to improve their potency and druglike character with the goal of identifying a clinical lead. Small libraries will be designed and used in molecular dynamics simulations, in order to study their binding modes. Ligands with promising binding behavior will be then synthesized and characterized in vitro and in vivo. Lampros during his postdoctoral experience at Memorial Sloan Kettering Cancer Center expects to develop advanced medicinal chemistry and computational skills as well as to gain experience in multiple in vitro biological assays and in vivo preclinical studies.


  1. Tschammer, N., Milanos, L.; Brox, R.; . Agonists of the chemokine receptor CXCR3. WO/2017/063910, Apr 20, 2017.


  1. Milanos, L.; Saleh, N.; Kling, R. C.; Kaindl, J.; Tschammer, N.; Clark, T., Identification of Two Distinct Sites for Antagonist and Biased Agonist Binding to the Human Chemokine Receptor CXCR3. Angew Chem Int Ed Engl 2016, 55 (49), 15277-15281.[doi]

  2. Milanos, L.; Brox, R.; Frank, T.; Poklukar, G.; Palmisano, R.; Waibel, R.; Einsiedel, J.; Durr, M.; Ivanovic-Burmazovic, I.; Larsen, O.; Hjorto, G. M.; Rosenkilde, M. M.; Tschammer, N., Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3. J Med Chem 2016, 59 (5), 2222-43.[doi]